Exchange: NASDAQ·Updated 02:07 PM EDT
CLDX logo

CLDXCelldex Therapeutics Inc.

$35.02
$0.40
(1.13%)
Today
EarningsAug 6
Mkt Cap$2.78B
Vol184,944.00
News
all
press releases
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Zacks
More News
CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?
Celldex announced that its experimental drug barzolvolimab missed key goals in a mid-stage study for prurigo nodularis.
Stocktwits
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?
Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval...
Yahoo! Finance: News
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva (INVA) delivered earnings and revenue surprises of +3.53% and -1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX
Pictet Asset Management Holding SA reduced its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 20.1% during the fourth quarter, according to the company in its most...
MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving Average - What's Next?
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving Average - Here's Why...
MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.